IAM C1
Alternative Names: CDK2/4 dual inhibitor - Iambic Therapeutics; IAM-C1Latest Information Update: 06 Jun 2024
At a glance
- Originator Iambic Therapeutics
- Class Antineoplastics; Small molecules
- Mechanism of Action Cyclin-dependent kinase 2 inhibitors; Cyclin-dependent kinase 4 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 28 Mar 2024 IAM C1 is available for licensing as of 28 Mar 2024. https://www.iambic.ai/partnerships
- 28 Mar 2024 Preclinical trials in Cancer in USA (unspecified route) (Iambic Therapeutics pipeline, March 2024)